Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

XBIO Relative to the S&P 500

XBIO Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Xenetic Biosciences, Inc. (NASD:XBIO) seasonal charts above shows that a Buy Date of May 16 and a Sell Date of August 4 has resulted in a geometric average return of 3.5% above the benchmark rate of the S&P 500 Total Return Index over the past 13 years. This seasonal timeframe has shown positive results compared to the benchmark in 9 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 13 years by an average of 46.98% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient s malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.

To download XBIO seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: XBIO